Former AstraZeneca Executive Lily Zhu Joins Yidu Cloud as General Manager; Ex-Eli Lilly Oncology Leader Yin Hang Appointed Head of Hengrui's Oncology Business

And on the afternoon of October 9, Li Li Zhu formally announced her retirement from AstraZeneca via email. Previously, she served as the head of AstraZeneca China's Digital and Commercial Innovation Department, and the Commercial Strategy and Operational Excellence Department.

Lily Zhu has over 30 years of experience in marketing management, digital innovation, and smart healthcare within multinational pharmaceutical companies. She has held core management positions at renowned enterprises such as Pfizer, Viatris, and AstraZeneca, where she repeatedly drove business model transformations and the construction of digital ecosystems.

Coincidentally,Hengrui Pharma Recently Appoints Yin Hang as General Manager of the Oncology DivisionHe will report directly to the CEO and join the company's China Management Committee, based in Shanghai.

Yin Hang graduated from the International Business Management program at Renmin University of China. He previously worked at Novo Nordisk and joined Eli Lilly China in April 2019 as the Marketing Director of the Oncology Division. In November 2020, Yin Hang became the head of the Breast Cancer line within the Oncology Division at Eli Lilly China. In August 2021, he was officially promoted to Vice President of the Oncology Division, a position he held until his departure in September this year.

After assuming the new role at Hengrui Pharma, Yin Hang will also temporarily serve as the head of the Aireni (Pyrotinib) line. Han Shu, Vice General Manager of the Oncology Division and head of the Comprehensive Oncology Line, as well as Peng Pai, Vice General Manager of the Oncology Division and head of the Tumor Immunotherapy Line, will report directly to him.

Siqi Circle Open Class Registration Now Open!